Ignite Creation Date:
2024-05-05 @ 4:37 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00278889
Status:
COMPLETED
Last Update Posted:
2012-10-24
First Post:
2006-01-17
Brief Title:
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic AcidLeucovorin F - Fluorouracil and OX - Oxaliplatin FOLFOX
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Study to Compare the Efficacy of AZD2171 in Combination With 5-fluorouracil Leucovorin and Oxaliplatin FOLFOX and the Efficacy of Bevacizumab in Combination With FOLFOX in the Second-line Treatment of Patients With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2012-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HORIZON I
Brief Summary:
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX in the second-line treatment of patients with metastatic colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HORIZON I | None | None | None |
| EUDRACT number 2005-003443-31 | None | None | None |